Philips showcases integrated diagnostic, therapy and compliance solutions at SLEEP 2014 - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Philips showcases integrated diagnostic, therapy and compliance solutions at SLEEP 2014 Patient engagement tools and long-term care support programs, teamed with diagnostic and therapy options, improve identification and treatment of sleep disorders


Philips showcases integrated diagnostic, therapy and compliance solutions at SLEEP 2014

Patient engagement tools and long-term care support programs, teamed with diagnostic and therapy options, improve identification and treatment of sleep disorders

PR Newswire

ANDOVER, Mass., June 2, 2014 /PRNewswire/ -- Philips Respironics, a division of Royal Philips (NYSE: PHG, AEX: PHIA), will showcase its latest sleep-disordered breathing solutions June 1-4 at SLEEP 2014, the 28th Annual Meeting of the Associated Professional Sleep Societies LLC (APSS).

Royal Philips

Philips will present innovations that span the continuum of care, helping to diagnose, treat and manage sleep disorders. Physicians will have the opportunity to see new options in home sleep testing, CPAP masks, and programs that enhance patient engagement and long-term care.

"Evidence shows that motivated, educated patients embrace therapy and participate more fully in their own care," says Teofilo Lee Chiong, M.D., Chief Medical Liaison, Philips Healthcare. "Philips is creating an ecosystem of medical devices and services, using smart technology, to empower patients and advance the effectiveness of sleep therapy."

At SLEEP 2014 in Minneapolis, MN, Philips will spotlight the following products and services that are part of the industry's broadest portfolio of insight-driven solutions.

Easy and reliable sleep testing in the home

The Alice NightOne home sleep testing system, which Philips will preview at SLEEP 2014, is making home sleep testing (HST) easy for patients and sleep professionals.

  • Intuitive design and a "smart guide" enable patients to set up the device on their own with confidence.
  • "Good Study Indicator" visually displays the amount of quality data in 25 percent increments, allowing the clinician to decide if the patient needs to repeat the study before returning the device.
  • Provides reliable data to differentiate between obstructive, central and positional sleep apnea.

Professional sleep and activity monitoring solutions

The Actiwatch Spectrum Plus and Actiwatch Spectrum PRO data collection devices provide accurate and objective activity, sleep, wake and light-exposure data.

  • Collects data on a variety of sleep parameters, 24/7, with advanced sensing capabilities.
  • Wristwatch functionality offers convenience for the wearer.
  • Actiwatch Spectrum PRO includes subjective scoring capabilities and audible and vibrational alarms.

Mask options as unique as each patient

Comfort is key to obstructive sleep apnea (OSA) patients using PAP therapy, and Philips' mask options account for the unique facial structure and breathing preferences. For the first time at the SLEEP conference, Philips' entire new mask lineup is available for attendees to see and experience.

  • Nuance and Nuance Pro, rated by patients as easier to assemble and use than the leading pillows mask.
  • Amara silicone and gel masks, both smaller and lighter than the current leading full face mask, with 60% fewer parts.
  • Wisp, which combines the performance and comfort of a nasal mask with the aesthetics of a pillows mask.

Patient engagement and long-term care support

The SleepMapper mobile and web-based self-management application is enabling patients to take a more active role in their therapy by providing vital support to those with OSA. The results of a study released at SLEEP 2014 show that patients using SleepMapper achieved a PAP therapy adherence rate that was 22% higher than non-users.

  • Works with EncoreAnywhere and most System One devices to provide a complete therapy and compliance solution.
  • Offers clinicians and home care providers multiple ways to connect to their patients, ensuring needed therapy support, efficient resupply, and ultimately, enhanced PAP adherence.

Bluetooth connectivity to assist patients and their care team

Philips will preview the System One Sleep therapy device with integrated Bluetooth technology. 

  • Combined with the EncoreAnywhere data management system, integrated Bluetooth technology provides OSA patients with a simple way to retrieve their PAP data through the SleepMapper self-management solution.
  • Offers homecare providers a cost-effective option for retrieving compliance information.

Visit booth #600 to see Philips Respironics' latest diagnostic, therapy, and compliance solutions. To learn how Philips is improving the quality of healthcare through innovative solutions, inspired by human insights, visit www.philips.com/healthcare and follow the #SLEEP2014 conversation @PhilipsResp.

For further information, please contact:
Alicia Cafardi
Philips Healthcare
Tel: +1 724-387-4439
E-mail: alicia.cafardi@philips.com

About Royal Philips:
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2013 sales of EUR 23.3 billion and employs approximately 112,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.

Logo - http://photos.prnewswire.com/prnh/20140122/NE50581LOGO

SOURCE Royal Philips

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here